Perpetual Observational Study - Ventilator Associated Pneumonia
POS-VAP: Perpetual Observational Study - Ventilator Associated Pneumonia
European Clinical Research Alliance for Infectious Diseases (ECRAID)
20,000 participants
Aug 3, 2022
OBSERVATIONAL
Summary
Ventilator-Associated Pneumonia (VAP) is a bacterial respiratory infection that patients in the Intensive Care Unit (ICU) often get when they cannot breathe for themselves and require mechanical ventilation. It is linked to higher chances of death, a longer stay in the hospital, higher costs, and the use of more antibiotics. Options to help prevent or treat this disease are in development and will require evaluation in future clinical trials. The goal of POS-VAP is to build and continuously train a network of ICUs to be prepared for doing these trials, to facilitate their execution.
Eligibility
Inclusion Criteria5
- Age≥18 years
- At risk of acquiring VAP during ICU stay, defined as:
- Requiring admission or being admitted to the ICU.
- Expected or documented to be under IMV for more than 48 hours.
- Consent, either a written informed consent given by the study patient in full medical, psychological, cognitive, social or legal capacity to give an informed consent, or, if not possible, by a Legally Authorized Representative of the study patient OR any applicable locally accepted form of consent OR consent waiver allowing data collection and sharing of data according to ECRAID's principles
Exclusion Criteria1
- Death is deemed to be imminent or inevitable during this hospital admission AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(35)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05719259